1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Specifications of predominant nonserious adverse events days 1–3 after intrathecal gadobutrol in various doses^{^a}
iNPH Cohort Non-iNPH Cohort
0.50 mmol (n = 21) 0.25 mmol (n = 94) 0.10 mmol (n = 29) 0.50 mmol (n = 35) 0.25 mmol (n = 17)
No adverse events (No.) (%) 9 (42.9%) 62 (66.0%) 26 (89.7%) 17 (47.2%) 5 (29.4%)
Adverse events present (No.) (%) 12 (57.1%) 32 (34.0%) 3 (10.3%) 18 (51.4%) 12 (70.6%)
Predominant adverse events 
 Mild headache, nausea, and/or dizziness (No.) (%) 2 (9.5%) 17 (18.1%) 1 (3.4%) 3 (8.3%) 2 (11.8%)
 Moderate headache, nausea, and/or dizziness (No.) (%) 5 (23.8%) 4 (4.3%) 1 (3.4%) 8 (22.9%) 6 (35.3%)
 Severe headache, nausea, and/or dizziness (No.) (%) 1 (4.8%) 1 (1.1%) 0 4 (11.1%) 0
 Back pain from spinal puncture (No.) (%) 2 (9.5%) 5 (5.3%) 1 (3.4%) 3 (8.6%) 3 (17.6%)
 Other (No.) (%) 2 (9.5%) 5 (5.3%) 0 0 1 (5.9%)
↵a Data are presented as the number of individuals (percentages are in parentheses).